Focus on HIV Care

Back to articles

Maraviroc: First CCR5 antagonist approved to treat HIV

KEY POINT

Maraviroc (Selzentry—Pfizer) is a novel medication recently approved by FDA for use in combination with other antiretroviral medications in treating adults with CCR5-tropic HIV-1–detectable disease.